Skip to search formSkip to main contentSkip to account menu
  • Publications
  • Influence
White matter changes caused by chronic solvent abuse.
TLDR
There are some patients with restricted but severe enough change to cause the neurologic symptoms in specific regions, such as the brain stem and/or cerebellum, before the brain atrophy becomes apparent, which suggests that the restricted white matter change represents not only an early change of diffuseWhite matter change, but at least in some cases also represents a qualitatively different change than that of diffusewhite matter change.
View on PubMed
Abnormal cerebral perfusion in chronic methamphetamine abusers: A study using 99mTC-HMPAO and spect
View on Elsevier
Effects of MRI abnormalities on WAIS‐R performance in solvent abusers
TLDR
The data indicate that solvent abuse causes the decline in the test performance reflecting cognitive and fine motor dysfunction and that white matter changes and pontine atrophy may have some roles in this decline.
View on Wiley
Regional cerebral blood flow abnormalities in chronic solvent abusers
TLDR
It is suggested that rCBF abnormalities, especially in the prefrontal cortex, develop in chronic solvent abusers, and that this frontal hypoperfusion may be a biological basis of amotivational syndrome.
View on Wiley
Symptomatological structure of volatile solvent-induced psychosis: is "solvent psychosis" a discernible syndrome?
TLDR
Clinical observations the "amotivational syndrome" may be a characteristic feature of patients suffering from solvent-induced psychosis and suggest "solvent psychosis" is a discernible syndrome, and is distinctive from psychotic symptoms of typical schizophrenia.
View on PubMed
T2 relaxometry in the central nervous system of solvent misusers
TLDR
Results confirmed T2 prolongation in the white matter with T2 shortening in the thalamus of solvent misusers with white matter changes, and provided further support for the classification ofwhite matter changes.
View on Wiley
[Clinical equivalence trial of UROCALUN miniaturized tablet in patients with upper urinary tract stone disease].
TLDR
It is suggested that the miniaturized tablet contributes to improve the medication compliance for patients and thus it is expected to improved the clinical efficacy of UROCALUN.
View on PubMed
Impact of the COVID-19 pandemic on patients with mental health problems and the differences among diagnostic categories
TLDR
One third of patients reported symptom deterioration during the COVID-19 pandemic, which was associated with stress and daily life changes, and patients with good adaptability to environmental changes might resilient against symptom deterioration.
View on SAGE
[Basic policy towards patient's violation of drug control law].
  • S. Hirai
  • Law, Medicine
    Nihon rinsho. Japanese journal of clinical…
  • 1 December 2003
TLDR
Medical workers should avoid prosecuting a patient for illegal drug use, so that drug users can seek help and try to put the patient in a situation where the patient's drug use in the future can be treated by the criminal justice system.
View on PubMed
[Drug therapy of Alzheimer's disease. Problems of the criteria of clinical trials of nootropic drugs].
  • S. Hirai
  • Medicine
    Nihon rinsho. Japanese journal of clinical…
  • 1 July 1988
View on PubMed
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License